{
    "organizations": [],
    "uuid": "044f548f35e937bf215394e6a322c74c30287179",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cymabay-announces-12-week-and-26-w/brief-cymabay-announces-12-week-and-26-week-results-from-phase-2-study-of-seladelpar-in-patients-with-primary-biliary-cholangitis-idUSFWN1RO0N1",
    "ord_in_thread": 0,
    "title": "BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News  52 AM / in 10 minutes BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis Reuters Staff 1 Min Read \nApril 11 (Reuters) - CymaBay Therapeutics Inc: \n* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESSâ„¢ 2018 * SELADELPAR APPEARS SAFE AND WELL TOLERATED \n* RESULTS FROM PHASE 2 OF SELADELPAR STUDY REAFFIRM PLANS FOR ADVANCING TO PHASE 3 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-04-11T14:50:00.000+03:00",
    "crawled": "2018-04-11T15:08:05.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "minute",
        "announces",
        "result",
        "phase",
        "study",
        "seladelpar",
        "patient",
        "primary",
        "biliary",
        "cholangitis",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "cymabay",
        "therapeutic",
        "inc",
        "week",
        "result",
        "ongoing",
        "phase",
        "study",
        "seladelpar",
        "patient",
        "primary",
        "biliary",
        "cholangitis",
        "international",
        "liver",
        "seladelpar",
        "appears",
        "safe",
        "well",
        "tolerated",
        "result",
        "phase",
        "seladelpar",
        "study",
        "reaffirm",
        "plan",
        "advancing",
        "phase",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}